{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:14:56Z","timestamp":1793672096369,"version":"4.5.1"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Area under the concentration\u2013time curve (AUC)-guided vancomycin treatment is associated with decreased nephrotoxicity. It is preferable to obtain two samples to estimate the AUC. This study examined the usefulness of AUC estimation via trough concentration (Cmin)-only sampling of 260 adults infected with methicillin-resistant Staphylococcus aureus (MRSA) who received vancomycin. The exact Cmin sampling time was used for Bayesian estimation. A significantly higher early treatment response was observed in patients with a day 2 AUC \u2265 400 \u00b5g\u00b7h\/mL than those with &lt;400 \u00b5g\u00b7h\/mL, and a significantly higher early nephrotoxicity rate was observed in patients with a day 2 AUC \u2265 600 \u00b5g\u00b7h\/mL than those with &lt;600 \u00b5g\u00b7h\/mL. These AUC cutoff values constituted independent factors for each outcome. In sub-analysis, the discrimination ability for early clinical outcomes using these AUC cutoffs was confirmed only in patients with q12 vancomycin administration. A significant difference in early treatment response using the 400 \u00b5g\u00b7h\/mL cutoff was obtained only in patients with low-risk infections. The usefulness of the vancomycin AUC target to decrease nephrotoxicity while assuring clinical efficacy was even confirmed with a single Cmin measurement. However, assessment with two samples might be required in patients with q24 administration or high\/moderate-risk MRSA infections.<\/jats:p>","DOI":"10.3390\/antibiotics11010096","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T10:57:37Z","timestamp":1642071457000},"page":"96","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Validation of Vancomycin Area under the Concentration\u2014Time Curve Estimation by the Bayesian Approach Using One-Point Samples for Predicting Clinical Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Infections"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-9050","authenticated-orcid":false,"given":"Takashi","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"},{"name":"Department of Clinical Infectious Diseases, Tokoname City Hospital, 3-3-3 Asukadai, Tokoname 479-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ichiki","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Prevention, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhito","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Public Health, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hyogo College of Medicine Hospital, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hyogo College of Medicine Hospital, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Takubo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hyogo College of Medicine Hospital, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ikeuchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2934-1680","authenticated-orcid":false,"given":"Motoi","family":"Uchino","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6990-425X","authenticated-orcid":false,"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Hospital, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1684","authenticated-orcid":false,"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto 860-8556, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hyogo College of Medicine Hospital, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectiousdiseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Men, P., Li, H.B., Zhai, S.D., and Zhao, R.S. (2016). Association between the AUC0-24\/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146224"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?","volume":"58","author":"Neely","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/2042098614523819","article-title":"Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining van-comycin safety","volume":"5","author":"Phillips","year":"2014","journal-title":"Ther. Adv. Drug. Saf."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tsutsuura, M., Moriyama, H., Kojima, N., Mizukami, Y., Tashiro, S., Osa, S., Enoki, Y., Taguchi, K., Oda, K., and Fujii, S. (2021). The monitoring of vancomycin: A systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05858-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s11095-021-03030-y","article-title":"Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application","volume":"38","author":"Oda","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among pa-tients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The Emperor\u2019s New Clothes: Prospective Observational Evaluation of the Association Between Initial Vancomycin Exposure and Failure Rates Among Adult Hospitalized Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","first-page":"100","article-title":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing","volume":"31","author":"Wayne","year":"2011","journal-title":"Inf. Suppl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","article-title":"Population pharmacokinetics of vancomycin in Japanese adult patients","volume":"20","author":"Yasuhara","year":"1998","journal-title":"Ther. Drug. Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10096-016-2691-z","article-title":"Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction","volume":"35","author":"Ueda","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10156-012-0519-z","article-title":"Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: A multi-institutional study","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ueda, T., Takesue, Y., Nakajima, K., Ichiki, K., Ishikawa, K., Takai, Y., Yamada, K., Tsuchida, T., Otani, N., and Takahashi, Y. (2020). Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 \u03bcg\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00424-3"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/1\/96\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:28:53Z","timestamp":1760365733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/1\/96"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["antibiotics11010096"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11010096","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]}}}